RNS Number : 5010N MaxCyte, Inc. 08 May 2024 MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2024 ROCKVILLE, MD , May 8, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
RNS Number : 5074N MaxCyte, Inc. 08 May 2024 MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance ROCKVILLE, MD , May 8, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
ROCKVILLE, Md., May 07, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative
RNS Number : 0863N MaxCyte, Inc. 03 May 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Notice of AGM Rockville, Maryland - May 3 , 2024: MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 8924M MaxCyte, Inc. 01 May 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, MD , May 1, 2024 : MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative
RNS Number : 0410K MaxCyte, Inc. 10 April 2024 MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 ROCKVILLE, MD , April 10, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT ), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 0634J MaxCyte, Inc. 03 April 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights and Block Listing Return ROCKVILLE, MD , April 3, 2024 : MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 9563I MaxCyte, Inc. 02 April 2024 MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) Be Biopharma to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell
